{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-034134","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2023-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.843961+00:00","generated_at":"2026-06-07T14:28:39.079249+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Perspective Therapeutics sells brachytherapy business to GT Medical","bullets":["Transaction expected to close Q1 2024; assets include Cesium-131 seed IP, equipment, Richland, WA lease.","Consideration: 0.5% equity in GT Medical plus tiered cash royalties over 4 years (3-5% on seed sales, 0.5% on GammaTile).","Company retains most liabilities (environmental, warranty, taxes, accounts payable) and all accounts receivable.","Sale aligns resources with lead-based alpha-particle therapy pipeline (melanoma VMT01, neuroendocrine VMT-α-NET).","GT Medical gains control of Cesium-131 seed production, expanding its GammaTile Therapy customer base."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-034134","json":"https://secwatch.observer/filing/0001437749-23-034134.json","markdown":"https://secwatch.observer/filing/0001437749-23-034134.md","text":"https://secwatch.observer/filing/0001437749-23-034134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000143774923034134/0001437749-23-034134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000143774923034134/isr20231208_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:28:39.079249+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd53f81cf33c238030409f9dd7daf17064193bd6","claim":"Perspective Therapeutics, Inc. entered into Asset Purchase Agreement with GT Medical Technologies, Inc. (effective 2023-12-07).","evidence_excerpt":"On December 7, 2023, Isoray Medical, Inc. (“ Medical ”), a Delaware corporation and wholly-owned subsidiary of Perspective Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into an Asset Purchase Agreement (the “ Asset Purchase Agreement ”) by and among Medical, the Company, and GT Medical Technologies, Inc., a Delaware corporation (“ GT Medical ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/728387/000143774923034134/0001437749-23-034134-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"GT Medical Technologies, Inc."},{"label":"Effective","value":"2023-12-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}